Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Loss of taste; This non-serious case was reported by a consumer and described the occurrence of taste loss in a 80-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included chronic obstructive pulmonary disease, atrial fibrillation and spinal stenosis. Concomitant products included oxycodone hydrochloride (Oxycodone) and metoprolol succinate (Metoprolol). On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced taste loss (Verbatim: Loss of taste). The outcome of the taste loss was unknown. It was unknown if the reporter considered the taste loss to be related to Shingrix. It was unknown if the company considered the taste loss to be related to Shingrix. Additional Information: GSK receipt date: 07-JUN-2025 Consumer stated that before loss of taste, both salt & sweet were intensified, way too strong for patient and patient would always been an addict of both most through life. Patient had antibiotics.
Atrial fibrillation; Chronic obstructive pulmonary disease; Spinal stenosis
OXYCODONE; METOPROLOL